← Leaderboards
Jeffrey B Driban
Tufts Medical Center
$7,818,959
Attributed
$7,818,959
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,322,089 · 4
FDA$496,870 · 2
By mechanism
R01$6,788,938 · 3
R24$533,151 · 1
U01$496,870 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “United States”
- Leonard Freedman · Leidos Biomedical Research, Inc.$818,172,357
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Lawrence Corey · Fred Hutchinson Cancer Center$638,373,375
- David Heimbrook · Leidos Biomedical Research, Inc.$632,657,800
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
Research focus
United StatesDegenerative PolyarthritisSeveritiesSamplingArticular CartilageJointsBody Mass IndexCartilagePersonsStrategic PlanningKnee OsteoarthritisDisabilityParticipantPainMagnetic Resonance ImagingLesionReplacement ArthroplastyBone MarrowEnd Stage DiseaseKneeBaseBiological MarkersCase ControlEffective Therapy
Grant awards (16)
Interpretation and Utility of Novel Composite Structural Endpoints of Cumulative Damage and Disease Activity in Knee Osteoarthritis$726,131
R01 · FY2025 · AR · contact PI
The OAI Collaborative Osteoarthritis Research Enterprise (OAI CORE) Knowledgebase$533,151
R24 · FY2025 · AR · contact PI
Environmental Factors Associated with the Development of Osteoarthritis$383,224
R01 · FY2025 · AR · contact PI
Interpretation and Utility of Novel Composite Structural Endpoints of Cumulative Damage and Disease Activity in Knee Osteoarthritis$895,944
R01 · FY2024 · AR · contact PI
Environmental Factors Associated with the Development of Osteoarthritis$698,506
R01 · FY2024 · AR · contact PI
Environmental Factors Associated with the Development of Osteoarthritis$659,439
R01 · FY2023 · AR · contact PI
Interpretation and Utility of Novel Composite Structural Endpoints of Cumulative Damage and Disease Activity in Knee Osteoarthritis$584,846
R01 · FY2023 · AR · contact PI
Interpretation and Utility of Novel Composite Structural Endpoints of Cumulative Damage and Disease Activity in Knee Osteoarthritis$201,964
R01 · FY2023 · AR · contact PI
Interpretation and Utility of Novel Composite Structural Endpoints of Cumulative Damage and Disease Activity in Knee Osteoarthritis$525,404
R01 · FY2022 · AR · contact PI
Interpretation and Utility of Novel Composite Structural Endpoints of Cumulative Damage and Disease Activity in Knee Osteoarthritis$627,942
R01 · FY2021 · AR · contact PI
DDT-BMQ-00086 End-Stage Knee Osteoarthritis as a Prognostic Biomarker for Knee Osteoarthritis Trials$247,783
U01 · FY2021 · FD · contact PI
Cumulative Damage and Disease Activity Metrics as Prognostic Enrichment Imaging Biomarkers for Knee Osteoarthritis Trials$249,087
U01 · FY2020 · FD · contact PI
Characterization of Rapidly Progressive Knee Osteoarthritis$364,438
R01 · FY2018 · AR · contact PI
Characterization of Rapidly Progressive Knee Osteoarthritis$364,438
R01 · FY2017 · AR · contact PI
Characterization of Rapidly Progressive Knee Osteoarthritis$362,915
R01 · FY2016 · AR · contact PI
Characterization of Rapidly Progressive Knee Osteoarthritis$393,747
R01 · FY2015 · AR · contact PI